Nirmatrelvir-d₉  (Synonyms: PF-07321332-d9)

Nirmatrelvir-d9 (PF-07321332-d9) is the deuterium labeled Nirmatrelvir (HY-138687)^[1].

Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs^[1].
3CL^PRO is responsible for cleaving polyproteins 1a and 1ab of SARS-CoV-2.1. Without the activity of the SARS-CoV-2 3CL^PRO, nonstructural proteins (including proteases) cannot be released to perform their functions, inhibiting viral replication^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

508.58

C₂₃H₂₃D₉F₃N₅O₄

2861202-76-6

2628280-40-8

O=C(NCC1)[C@@H]1C[C@@H](C#N)NC([C@@H]2[C@]3([H])[C@@](CN2C([C@H](C(C([2H])([2H])[2H])(C([2H])([2H])[2H])C([2H])([2H])[2H])NC(C(F)(F)F)=O)=O)([H])C3(C)C)=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-223.  [Content Brief]